UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications

Clinical and translational science, 2022-12, Vol.15 (12), p.2989-2999

2022

Volltextzugriff (PDF)

Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects

The Journal of pharmacology and experimental therapeutics, 2021-08, Vol.378 (2), p.87-95

2021

Volltextzugriff (PDF)

Role of human pregnane X receptor in tamoxifen- and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells

Drug metabolism and disposition, 2008-05, Vol.36 (5), p.946-954

2008

Volltextzugriff (PDF)

Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen

Drug metabolism and disposition, 2002-05, Vol.30 (5), p.608-612

2002

Volltextzugriff (PDF)

Defining the Role of Gut Bacteria in the Metabolism of Deleobuvir: In Vitro and In Vivo Studies

Drug metabolism and disposition, 2015-10, Vol.43 (10), p.1612-1618

2015

Volltextzugriff (PDF)

Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients

The Journal of pharmacology and experimental therapeutics, 2014-11, Vol.351 (2), p.403-412

2014

Volltextzugriff (PDF)

Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells

Drug metabolism and disposition, 2011-11, Vol.39 (11), p.2093-2102

2011

Volltextzugriff (PDF)

Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes

Drug metabolism and disposition, 2016-03, Vol.44 (3), p.466-475

2016

Volltextzugriff (PDF)

Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor

Antimicrobial agents and chemotherapy, 2015-01, Vol.59 (1), p.25-37

2015

Volltextzugriff (PDF)

Induction of CYP3A4 by Efavirenz in Primary Human Hepatocytes: Comparison With Rifampin and Phenobarbital

Journal of clinical pharmacology, 2004-11, Vol.44 (11), p.1273-1281

2004

Volltextzugriff (PDF)

PII: S0887-2333(05)00203-1

Toxicology in vitro, 2006, Vol.20 (2), p.133-134

2006

Volltextzugriff (PDF)

Metabolism and Pharmacokinetics of Anti-Cancer Drugs

Toxicology in vitro, 2006-03, Vol.20 (2), p.133

2006

Volltextzugriff (PDF)

Cemento-Ossifying Fibroma of the Mandible: A Case Report

Curēus (Palo Alto, CA), 2024-02

2024

Volltextzugriff (PDF)

Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model

Cancer chemotherapy and pharmacology, 2022-05, Vol.89 (5), p.707-720

2022

Volltextzugriff (PDF)

Understanding CYP3A4 and P-GP mediated drug-drug interactions through PBPK modeling - case example of pralsetinib

Drug metabolism and pharmacokinetics, 2024-04, Vol.55, p.100969, Article 100969

2024

Volltextzugriff (PDF)

Quantitative Prediction of OATP‐Mediated Drug‐Drug Interactions With Model‐Based Analysis of Endogenous Biomarker Kinetics

CPT: pharmacometrics and systems pharmacology, 2018-08, Vol.7 (8), p.517-524

2018

Volltextzugriff (PDF)

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib

Cancer chemotherapy and pharmacology, 2021-12, Vol.88 (6), p.921-930

2021

Volltextzugriff (PDF)

The effect of BI 409306 on heart rate in healthy volunteers: a randomised, double-blind, placebo-controlled, crossover study

European journal of clinical pharmacology, 2022-05, Vol.78 (5), p.801-812

2022

Volltextzugriff (PDF)

Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations

Clinical and translational science, 2024-06, Vol.17 (6), p.e13818-n/a

2024

Volltextzugriff (PDF)

Comparative Evaluation of Different Alveolar Ridge Width Measurement Techniques in Dental Implant Treatment Planning: An in Vivo Observational Non-Interventional Study

Indian journal of otolaryngology, and head, and neck surgery, 2024-02, Vol.76 (1), p.365-373

2024

Volltextzugriff (PDF)

Bivalirudin and sirolimus co-eluting coronary stent: Potential strategy for the prevention of stent thrombosis and restenosis

International journal of pharmaceutics, 2021-05, Vol.600, p.120403, Article 120403

2021

Volltextzugriff (PDF)

Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib

CPT: pharmacometrics and systems pharmacology, 2024-04, Vol.13 (4), p.660-672

2024

Volltextzugriff (PDF)

Evaluation of Patient‐Centric Sample Collection Technologies for Pharmacokinetic Assessment of Large and Small Molecules

Clinical pharmacology and therapeutics, 2024-09, Vol.116 (3), p.782-794

2024

Volltextzugriff (PDF)

Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics

Pharmaceutics, 2024-04, Vol.16 (4), p.564

2024

Volltextzugriff (PDF)

Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients

Journal of clinical pharmacology, 2021-12, Vol.61 (12), p.1579-1591

2021

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(29)

Publikationsform

Sprache

Englisch
(45)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications

Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects

Role of human pregnane X receptor in tamoxifen- and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells

Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen

Defining the Role of Gut Bacteria in the Metabolism of Deleobuvir: In Vitro and In Vivo Studies

Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients

Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells

Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes

Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor

Induction of CYP3A4 by Efavirenz in Primary Human Hepatocytes: Comparison With Rifampin and Phenobarbital

PII: S0887-2333(05)00203-1

Metabolism and Pharmacokinetics of Anti-Cancer Drugs

Cemento-Ossifying Fibroma of the Mandible: A Case Report

Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model

Understanding CYP3A4 and P-GP mediated drug-drug interactions through PBPK modeling - case example of pralsetinib

Quantitative Prediction of OATP‐Mediated Drug‐Drug Interactions With Model‐Based Analysis of Endogenous Biomarker Kinetics

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib

The effect of BI 409306 on heart rate in healthy volunteers: a randomised, double-blind, placebo-controlled, crossover study

Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations

Comparative Evaluation of Different Alveolar Ridge Width Measurement Techniques in Dental Implant Treatment Planning: An in Vivo Observational Non-Interventional Study

Bivalirudin and sirolimus co-eluting coronary stent: Potential strategy for the prevention of stent thrombosis and restenosis

Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib

Evaluation of Patient‐Centric Sample Collection Technologies for Pharmacokinetic Assessment of Large and Small Molecules

Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics

Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients

Suchergebnisse filtern